University of Cincinnati, Metabolic Diseases Institute, Department of Pathology, Cincinnati, OH 45236-507, USA.
Placenta. 2011 Mar;32 Suppl 2(0 2):S218-21. doi: 10.1016/j.placenta.2011.01.011.
Data obtained from recent studies in humans, rodents, and cell culture demonstrate that circulating maternal cholesterol can be transported to the fetus. The two major cell types responsible for the transport are trophoblasts and endothelial cells of the fetoplacental vasculature. Maternal lipoprotein-cholesterol is initially taken up by trophoblasts via receptor-mediated and receptor-independent processes, is transported by any number of the sterol transport proteins expressed by cells, and is effluxed or secreted out of the basal side via protein-mediated processes or by aqueous diffusion. This cholesterol is then taken up by the endothelium and effluxed to acceptors within the fetal circulation. The ability to manipulate the mass of maternal cholesterol that is taken up by the placenta and crosses to the fetus could positively impact development of fetuses affected with the Smith-Lemli-Opitz Syndrome (SLOS) that have reduced ability to synthesize cholesterol and possibly impact growth of fetuses unaffected by SLOS but with low birthweights.
最近在人类、啮齿动物和细胞培养中获得的数据表明,循环母体胆固醇可以转运到胎儿。负责转运的两种主要细胞类型是滋养层细胞和胎盘中血管内皮细胞。母体脂蛋白胆固醇最初通过受体介导和非受体介导的过程被滋养层细胞摄取,通过细胞表达的多种固醇转运蛋白进行运输,并通过蛋白介导的过程或通过水性扩散从基底外侧外排或分泌出去。然后,这种胆固醇被内皮细胞摄取,并外排到胎儿循环中的受体中。操纵胎盘摄取并转运到胎儿的母体胆固醇的量的能力可能会对患有 Smith-Lemli-Opitz 综合征 (SLOS) 的胎儿的发育产生积极影响,这些胎儿合成胆固醇的能力降低,并且可能会影响不受 SLOS 影响但出生体重低的胎儿的生长。